This website uses cookies to improve the site and user experience. By continuing to browse this site,
you agree to accept our use of cookies. For more information, please review our Cookies Policy
SITC 2022
Presentations
Disitimab Vedotin | Urothelial Carcinoma | Abstract #663
Phase 2 multi-cohort clinical study evaluating Disitamab Vedotin alone and in combination with pembrolizumab in patients with HER2-expressing unresectable or metastatic urothelial carcinoma (rc48g001, trial in progress)